OncoSil MEDICAL Ltd

New Technology To Provide Safer Radiotherapy Treatments

Investor Update March 2015

Action Plan 2015

ASX: OSL

Important Notice

The purpose of the presentation is to provide an update of the business of OncoSil Medical Ltd (ASX:OSL). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by OncoSil Medical Ltd and should not be relied upon as an independent source of information. Please contact OncoSil Medical Ltd and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. None of OncoSil Medical Ltd, or any of its affiliates or associated companies(or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside OncoSil Medical Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and OncoSil Medical Ltd's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events. This presentation should not be relied on as a recommendation or forecast by OncoSil Medical Ltd. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Pancreatic Cancer

OncoSil MEDICAL Ltd
New Technology To Provide Safer Radiotherapy Treatments

Unmet Medical need

- 280,000+ pancreatic cancer incidence yearly world wide (1)
- Approximately 45,000 new patients diagnosed with pancreatic cancer in the US each year
- Poor prognosis -Median survival ~8 months and 5 year survival less than 7%

Target Market

- World market for pancreatic drugs is projected to exceed $1.2b by 2015 (2)
- Current Chemo regime in excess of $60,000 per annum

Source (1) – 2010 World Cancer Research Fund Source (2)– Global Industry Analysis

Patient Pool assumptions – US & EU Only Locally Advanced

US new cases pa: 46,000
EU new cases pa: 85,000



Potential Market Size (>105,000 pts p.a)

Total Market Opportunity (>$1 Billion)

Clinical Trials Completed

- BIOSP-201: A single dose, single centre open label phase I/II safety study in hepatocarcinoma, recruitment 31 May 2004 – 09 March 2005, 8 patients enrolled
- BIOSP-202: A multi-centre, dose escalating study in hepatocarcinoma, recruitment 17 Oct 2005 – 27 Sept 2006, 11 patients enrolled
- DB2-201: A multi-centre, open label, phase IIa, safety study in patients with advanced unresectable adenocarcinoma of the pancreas, recruitment 16 Sept 2006 – 21 Jan 2008, 17 patients enrolled
- DB2-202: A multi-centre, open label, phase IIb, dose escalating safety study in patients with advanced unresectable adenocarcinoma of the pancreas, recruitment 30 Jun 2008 – 12 Aug 2009, 6 patients enrolled

Pancreatic cancer: Clinical data to date

OncoSil MEDICAL Ltd
New Technology To Provide Safer Radiotherapy Treatments

Clinical Trial Results

- 17 locally advanced pancreatic cancer patients in single arm study
- Significant anti-cancer activity – **disease control rate of 82%** : 4 Partial Responses, 10 Stable disease and 3 Progressive Disease
- Average reduction in pain of 35% - with a maximum reduction of 69% between weeks 8 and 11 following implant
- Median progression free survival was 121 days
- Median overall survival was 309 days or 10+ months (compared with a typical 5.7 months with gemcitabine alone)

OncoSil Corporate Goals: 2015

- Finalize design of Pivotal Study for Pancreatic cancer protocol by end of Q2 2015
- Recruit 1st patient in Pivotal Study by end of Q3 2015
- CE Mark approval by end Q3 2015
- IDE approval by Q4 2015

Global Regulatory Strategy

Device Registration Plan for Key Pharmaceutical Markets



OncoSil's global registration strategy is with CE (Conformité Européenne) mark, and with the United States FDA (Food and Drug Administration. IDE: Investigational Device Exemption.

Organisational Chart



* Short term Contract position (3-6 months), with view to permanent role

Capital Structure

ASX code	**OSL**
Market Cap (February, 2015)	**$A29m**
Shares on issue	**355m**
Cash (31 December, 2014)	**$A6.3m**
R&D Credits & Pre-payments	**$A2.55 M**
Total Cash and Credits	**$A8.85M**

Average Burn rate: $A 460K per month

Cash reserves to Q4 2016

Investment Thesis

1. OncoSil Medical has strong leadership
    - New management, energised and focused.
2. High unmet medical need.
    - Pancreatic cancer has one year survival of 26% and five year survival of 6%
3. Current treatments are lacking.
    - Gemcitabine was approved 18 years ago.
    - Abraxane (approved 2013)
    - Median overall survival has increased by 2 months to 8.5 months over the past 20 years
4. Sufficient Clinical Data to secure CE mark in Q3 2015.
5. EU Commercialisation in 2015 possible following CE Mark authorisation.
6. Single Pivotal Study sufficient to secure FDA PMA approval.
7. Pivotal Study to commence ‘active recruitment’ in Q3 2015.